دورية أكاديمية
أعرض في EDS

Spleen tyrosine kinase inhibitor R406 has both antiviral and anti-inflammatory effects on severe influenza A infection.

التفاصيل البيبلوغرافية
العنوان: Spleen tyrosine kinase inhibitor R406 has both antiviral and anti-inflammatory effects on severe influenza A infection.
المؤلفون: Luo J; NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology and Viral Diseases, Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China., Gao Y; NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology and Viral Diseases, Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China., Guo W; NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology and Viral Diseases, Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.; National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China., Zhao S; NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology and Viral Diseases, Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China., Li L; NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology and Viral Diseases, Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China., Zhang Z; NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology and Viral Diseases, Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China., Gao R; NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology and Viral Diseases, Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
المصدر: Journal of medical virology [J Med Virol] 2024 May; Vol. 96 (5), pp. e29678.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE
أسماء مطبوعة: Publication: New York Ny : Wiley-Liss
Original Publication: New York, Liss.
مواضيع طبية MeSH: Syk Kinase*/antagonists & inhibitors , Antiviral Agents*/pharmacology , Antiviral Agents*/therapeutic use , Orthomyxoviridae Infections*/drug therapy , Orthomyxoviridae Infections*/immunology , Anti-Inflammatory Agents*/pharmacology , Anti-Inflammatory Agents*/therapeutic use , Oxazines*/pharmacology , Oxazines*/therapeutic use , Disease Models, Animal*, Animals ; Humans ; Mice ; Pyridines/pharmacology ; Pyridines/therapeutic use ; Imidazoles/pharmacology ; Imidazoles/therapeutic use ; Lung/pathology ; Lung/virology ; Lung/drug effects ; Lung/immunology ; A549 Cells ; Influenza A virus/drug effects ; Mice, Inbred BALB C ; Oseltamivir/pharmacology ; Oseltamivir/therapeutic use ; Influenza, Human/drug therapy ; Influenza, Human/immunology ; THP-1 Cells ; Female ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Tyrosine Kinase Inhibitors
مستخلص: Death due to severe influenza is usually a fatal complication of a dysregulated immune response more than the acute virulence of an infectious agent. Although spleen tyrosine kinase (SYK) as a critical immune signaling molecule and therapeutic target plays roles in airway inflammation and acute lung injury, the role of SYK in influenza virus infection is not clear. Here, we investigated the antiviral and anti-inflammatory effects of SYK inhibitor R406 on influenza infection through a coculture model of human alveolar epithelial (A549) and macrophage (THP-1) cell lines and mouse model. The results showed that R406 treatment increased the viability of A549 and decreased the pathogenicity and mortality of lethal influenza virus in mice with influenza A infection, decreased levels of intracellular signaling molecules under the condition of inflammation during influenza virus infection. Combination therapy with oseltamivir further ameliorated histopathological damage in the lungs of mice and further delayed the initial time to death compared with R406 treatment alone. This study demonstrated that phosphorylation of SYK is involved in the pathogenesis of influenza, and R406 has antiviral and anti-inflammatory effects on the treatment of the disease, which may be realized through multiple pathways, including the already reported SYK/STAT/IFNs-mediated antiviral pathway, as well as TNF-α/SYK- and SYK/Akt-based immunomodulation pathway.
(© 2024 Wiley Periodicals LLC.)
References: Belshe RB. The origins of pandemic influenza—lessons from the 1918 virus. N Engl J Med. 2005;353(21):2209‐2211.
Smith GJD, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine‐origin H1N1 influenza A epidemic. Nature. 2009;459(7250):1122‐1125.
Organization WH. Influenza (Seasonal). 2023. Accessed October 3, 2023. https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).
Organization WH. World Health Statistics. 2014. Accessed May 15, 2014. https://iris.who.int/bitstream/handle/10665/112738/9789240692671_eng.pdf;jsessionid=67E446804BFC8C8A73EDA546FD58B7CD?sequence=1.
Sarda C, Palma P, Rello J. Severe influenza: overview in critically ill patients. Curr Opin Crit Care. 2019;25(5):449‐457.
Valenzuela‐Sánchez F, Valenzuela‐Méndez B, Rodríguez‐Gutiérrez JF, Rello J. Personalized medicine in severe influenza. Eur J Clin Microbiol Infect Dis. 2016;35(6):893‐897.
Geahlen RL. Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci. 2014;35(8):414‐422.
Zhang Y, Oh H, Burton RA, Burgner JW, Geahlen RL, Post CB. Tyr130 phosphorylation triggers Syk release from antigen receptor by long‐distance conformational uncoupling. Proc Natl Acad Sci. 2008;105(33):11760‐11765.
Simon M, Vanes L, Geahlen RL, Tybulewicz VLJ. Distinct roles for the linker region tyrosines of Syk in FcepsilonRI signaling in primary mast cells. J Biol Chem. 2005;280(6):4510‐4517.
Mócsai A, Abram CL, Jakus Z, Hu Y, Lanier LL, Lowell CA. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine‐based activation motifs. Nat Immunol. 2006;7(12):1326‐1333.
Yi Y‐S, Son Y‐J, Ryou C, Sung GH, Kim JH, Cho JY. Functional roles of Syk in macrophage‐mediated inflammatory responses. Mediators Inflamm. 2014;2014:1‐12.
Nadeem A, Ahmad SF, Al‐Harbi NO, et al. Inhibition of spleen tyrosine kinase signaling protects against acute lung injury through blockade of NADPH oxidase and IL‐17A in neutrophils and γδ T cells respectively in mice. Int Immunopharmacol. 2019;68:39‐47.
Furlong MT, Mahrenholz AM, Kim KH, Ashendel CL, Harrison ML, Geahlen RL. Identification of the major sites of autophosphorylation of the murine protein‐tyrosine kinase Syk. Biochim Biophys Acta (BBA) ‐ Mol Cell Res. 1997;1355(2):177‐190.
Wang L, Aschenbrenner D, Zeng Z, et al. Author Correction: gain‐of‐function variants in Syk cause immune dysregulation and systemic inflammation in humans and mice. Nat Genet. 2022;54(2):213.
Gao Y, Zhao D, Liu P, et al. The investigation on the role of spleen tyrosine kinase in hospitalized pneumonia patients: a potential biomarker for pneumonia process. Biomed J Sci Tech Res. 2022;43(5):35080‐35089.
Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex‐mediated inflammation. J Pharmacol Exp Ther. 2006;319(3):998‐1008.
Chen L, Monti S, Juszczynski P, et al. Syk‐dependent tonic B‐cell receptor signaling is a rational treatment target in diffuse large B‐cell lymphoma. Blood. 2008;111(4):2230‐2237.
Tassiulas I, Hu X, Ho H, et al. Amplification of IFN‐α‐induced STAT1 activation and inflammatory function by Syk and ITAM‐containing adaptors. Nature Immunol. 2004;5(11):1181‐1189.
Decker T, Stockinger S, Karaghiosoff M, Müller M, Kovarik P. IFNs and STATs in innate immunity to microorganisms. J Clin Invest. 2002;109(10):1271‐1277.
Underhill DM, Rossnagle E, Lowell CA, Simmons RM. Dectin‐1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood. 2005;106(7):2543‐2550.
Rogers NC, Slack EC, Edwards AD, et al. Syk‐dependent cytokine induction by Dectin‐1 reveals a novel pattern recognition pathway for C type lectins. Immunity. 2005;22(4):507‐517.
Marakalala MJ, Graham LM, Brown GD. The role of Syk/CARD9‐coupled C‐type lectin receptors in immunity to Mycobacterium tuberculosis infections. Clin Dev Immunol. 2010;2010:1‐9.
Yun Y, Chen J, Wang X, et al. Tofacitinib ameliorates lipopolysaccharide‐induced acute kidney injury by blocking the JAK‐STAT1/STAT3 signaling pathway. BioMed Res Int. 2021;2021:1‐9.
Xie L‐B, Chen B, Liao X, et al. LINC00963 targeting miR‐128‐3p promotes acute kidney injury process by activating JAK2/STAT1 pathway. J Cell Mol Med. 2020;24(10):5555‐5564.
Li T, Li L, Peng R, et al. Abrocitinib attenuates microglia‐mediated neuroinflammation after traumatic brain injury via inhibiting the JAK1/STAT1/NF‐κB pathway. Cells. 2022;11(22):3588.
Pandey P, Al Rumaih Z, Kels MJT, et al. Therapeutic targeting of inflammation and virus simultaneously ameliorates influenza pneumonia and protects from morbidity and mortality. Viruses. 2023;15(2):318.
Li Y, Liu S, Chen Y, et al. Syk facilitates influenza A virus replication by restraining innate immunity at the late stage of viral infection. J Virol. 2022;96(7):e0020022.
Fütterer K, Wong J, Grucza RA, Chan AC, Waksman G. Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol. 1998;281(3):523‐537.
Grucza RA, Fütterer K, Chan AC, Waksman G. Thermodynamic study of the binding of the tandem‐SH2 domain of the Syk kinase to a dually phosphorylated ITAM peptide: evidence for two conformers. Biochemistry. 1999;38(16):5024‐5033.
Takada Y, Aggarwal BB. TNF activates Syk protein tyrosine kinase leading to TNF‐induced MAPK activation, NF‐κB activation, and apoptosis. J Immunol. 2004;173(2):1066‐1077.
Liu Q, Hua L, Bao C, et al. Inhibition of spleen tyrosine kinase restores glucocorticoid sensitivity to improve steroid‐resistant asthma. Front Pharmacol. 2022;13:885053.
Ehrhardt C, Ludwig S. A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell Microbiol. 2009;11(6):863‐871.
Hirata N, Suizu F, Matsuda‐Lennikov M, Edamura T, Bala J, Noguchi M. Inhibition of Akt kinase activity suppresses entry and replication of influenza virus. Biochem Biophys Res Commun. 2014;450(1):891‐898.
Hatton O, Phillips LK, Vaysberg M, Hurwich J, Krams SM, Martinez OM. Syk activation of phosphatidylinositol 3‐kinase/Akt prevents HtrA2‐dependent loss of X‐linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein‐Barr virus+ (EBV+) B cell lymphomas. J Biol Chem. 2011;286(43):37368‐37378.
Hatton O, Lambert SL, Krams SM, Martinez OM. Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein‐Barr virus (EBV)+ B cell lymphomas. PLoS One. 2012;7(8):e42610.
Jiang K, Zhong B, Ritchey C, et al. Regulation of Akt‐dependent cell survival by Syk and Rac. Blood. 2003;101(1):236‐244.
Moon KD, Post CB, Durden DL, et al. Molecular basis for a direct interaction between the Syk protein‐tyrosine kinase and phosphoinositide 3‐kinase. J Biol Chem. 2005;280(2):1543‐1551.
Tang Y, Su R, Gu Q, Hu Y, Yang H. PI3K/AKT‐mediated autophagy inhibition facilitates mast cell activation to enhance severe inflammatory lung injury in influenza A virus‐ and secondary Staphylococcus aureus‐infected mice. Antiviral Res. 2023;209:105502.
Sandilands E, Schoenherr C, Frame MC. p70S6K is regulated by focal adhesion kinase and is required for Src‐selective autophagy. Cell Signal. 2015;27(9):1816‐1823.
Blommaart EFC, Luiken JJFP, Blommaart PJE, van Woerkom GM, Meijer AJ. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J Biol Chem. 1995;270(5):2320‐2326.
Liu S, Liu S, Yu Z, et al. STAT3 regulates antiviral immunity by suppressing excessive interferon signaling. Cell Rep. 2023;42(7):112806.
Percopo CM, Ma M, Brenner TA, et al. Critical adverse impact of IL‐6 in acute pneumovirus infection. J Immunol. 2019;202(3):871‐882.
Schmit T, Guo K, Tripathi JK, et al. Interferon‐γ promotes monocyte‐mediated lung injury during influenza infection. Cell Rep. 2022;38(9):110456.
Hill DL, Whyte CE, Innocentin S, et al. Impaired HA‐specific T follicular helper cell and antibody responses to influenza vaccination are linked to inflammation in humans. eLife. 2021;10:e70554.
Liu X, Yang Z, Yuan J, et al. Early antibody response contributes to the virus eradication and clinical recovery of H7N9 influenza infection. Ann Clin Lab Sci. 2017;47(5):592‐599.
معلومات مُعتمدة: National Key Research and Development Program of China; 81971946 National Natural Scientific Foundation of China
فهرسة مساهمة: Keywords: R406; SYK; SYK inhibitor; immunotherapeutic target; influenza virus; spleen tyrosine kinase
تواريخ الأحداث: Date Created: 20240516 Date Completed: 20240516 Latest Revision: 20240516
رمز التحديث: 20240516
DOI: 10.1002/jmv.29678
PMID: 38751128
قاعدة البيانات: MEDLINE
الوصف
تدمد:1096-9071
DOI:10.1002/jmv.29678